{"id":23407,"date":"2019-12-12T00:48:22","date_gmt":"2019-12-12T00:48:22","guid":{"rendered":"https:\/\/wames.org.uk\/cms-english\/?p=23407"},"modified":"2019-12-12T00:48:22","modified_gmt":"2019-12-12T00:48:22","slug":"circulating-levels-of-gdf15-in-patients-with-me-cfs","status":"publish","type":"post","link":"https:\/\/wames.org.uk\/cms-english\/circulating-levels-of-gdf15-in-patients-with-me-cfs\/","title":{"rendered":"Circulating levels of GDF15 in patients with ME\/CFS"},"content":{"rendered":"

Circulating levels of GDF15 in patients with myalgic encephalomyelitis\/chronic fatigue syndrome,<\/a> by A Melvin,\u00a0E Lacerda,\u00a0H M Dockrell,\u00a0S O\u2019Rahilly\u00a0&\u00a0L Nacul in<\/span> Journal of Translational Medicine<\/em> vol 17, no. 409 (2019)<\/h3>\n

 <\/p>\n

Research abstract:<\/strong><\/h3>\n

Background:<\/strong>
\nMyalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) is a debilitating condition characterised by fatigue and post-exertional malaise. Its pathogenesis is poorly understood. GDF15<\/a> is a circulating protein secreted by cells in response to a variety of stressors. The receptor for GDF15 is expressed in the brain, where its activation results in a range of responses. Among the conditions in which circulating GDF15 levels are highly elevated are mitochondrial disorders, where early skeletal muscle fatigue is a key symptom. We hypothesised that GDF15 may represent a marker of cellular stress in ME\/CFS.<\/p>\n

Methods:<\/strong>
\nGDF15 was measured in serum from patients with ME\/CFS (n\u2009=\u2009150; 100 with mild\/moderate and 50 with severe symptoms), \u201chealthy volunteers\u201d (n\u2009=\u2009150) and a cohort of patients with multiple sclerosis (n\u2009=\u200950).<\/p>\n

Results:<\/strong>
\n\"\"<\/a>Circulating GDF15 remained stable in a subset of ME\/CFS patients when sampled on two occasions\u2009~\u20097\u00a0months (IQR 6.7\u20138.8) apart, 720\u00a0pg\/ml (95% CI 625\u2013816) vs 670\u00a0pg\/ml (95% CI 598\u2013796),\u00a0P\u2009=\u20090.5. GDF15 levels were 491\u00a0pg\/ml in controls (95% CI 429\u2013553), 546\u00a0pg\/ml (95% CI 478\u2013614) in MS patients, 560\u00a0pg\/ml (95% CI 502\u2013617) in mild\/moderate ME\/CFS patients and 602\u00a0pg\/ml (95% CI 531\u2013674) in severely affected ME\/CFS patients. Accounting for potential confounders, severely affected ME\/CFS patients had GDF15 concentrations that were significantly increased compared to healthy controls<\/strong> (P\u2009=\u20090.01). GDF15 levels were positively correlated (P\u2009=\u20090.026) with fatigue scores in ME\/CFS.<\/p>\n

Conclusions:<\/strong>
\nSevere ME\/CFS is associated with increased levels of GDF15, a circulating biomarker of cellular stress that appears which stable over several months.<\/p>\n","protected":false},"excerpt":{"rendered":"

Circulating levels of GDF15 in patients with myalgic encephalomyelitis\/chronic fatigue syndrome, by A Melvin,\u00a0E Lacerda,\u00a0H M Dockrell,\u00a0S O\u2019Rahilly\u00a0&\u00a0L Nacul in Journal of Translational Medicine vol 17, no. 409 (2019)   Research abstract: Background: Myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) is a … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[5447,3425,5448,3529,5449,4973],"class_list":["post-23407","post","type-post","status-publish","format-standard","hentry","category-news","tag-audrey-melvin","tag-dr-luis-nacul","tag-dr-stephen-orahilly","tag-eliana-m-lacerda","tag-gdf15","tag-hazel-m-dockrell"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p5qkYK-65x","_links":{"self":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/23407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/comments?post=23407"}],"version-history":[{"count":3,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/23407\/revisions"}],"predecessor-version":[{"id":23445,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/23407\/revisions\/23445"}],"wp:attachment":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/media?parent=23407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/categories?post=23407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/tags?post=23407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}